Frontal Fibrosing Alopecia: Pathogenesis, Clinical Features, and Emerging Treatments

Conclusions

• Frontal fibrosing alopecia is a complex scarring alopecia that is increasingly recognized across diverse ages, sexes, and skin types, but its underlying cause remains incompletely understood.
• Early recognition matters because FFA can progress permanently and is associated with substantial cosmetic impact, psychosocial distress, and reduced quality of life.
• Disease severity appears to be associated with features such as eyelash loss, facial papules, and body hair involvement, while eyebrow loss as an initial sign may indicate a milder course.
• Current management is multimodal and focuses on suppressing inflammation while also promoting hair growth, using treatments such as corticosteroids, anti-inflammatory agents, 5-alpha reductase inhibitors, and oral minoxidil.
• Antiandrogen therapies such as finasteride and dutasteride appear beneficial in many patients, supporting at least a partial hormonal contribution to the disease.
• Genetic studies suggest that FFA has a measurable inherited component, including susceptibility loci in HLA and related antigen-processing pathways.
• Environmental exposures, especially facial skin-care products, sunscreens, allergens, lifestyle factors, and diet, may contribute to disease risk or activity in susceptible patients.
• Emerging data support a possible role for environmental signaling pathways such as aryl hydrocarbon receptor activation, but this link still needs confirmation.
• Neurogenic inflammation may be an important component of FFA, as patients can have burning, pain, itch, sweating, and abnormal neuropeptide expression even in clinically unaffected scalp.
• Quantitative sensory testing suggests that sensory abnormalities extend beyond visible lesions, implying that treatment may need to target the broader scalp rather than only clinically obvious areas.
• New histopathologic findings involving adipose tissue and eccrine structures suggest that FFA may involve deeper follicular and dermal changes than previously appreciated.
• Overall, the field is moving toward better phenotyping, standardized trials, and mechanism-based treatments, but further research is still needed to define the disease and optimize therapy.